



Provided by the author(s) and University of Galway in accordance with publisher policies. Please cite the published version when available.

Title	Histological stroke clot analysis after thrombectomy: Technical aspects and recommendations
Author(s)	Staessens, S.; Fitzgerald, Seán; Andersson, T.; Clarençon, F.; Denorme, F.; Gounis, M. J.; Hacke, W.; Liebeskind, D. S.; Szikora, I.; van Es, A. C. G. M.; Brinjikji, W.; Doyle, Karen M.; De Meyer, S. F.
Publication Date	2019-11-03
Publication Information	Staessens, S., Fitzgerald, S., Andersson, T., Clarençon, F., Denorme, F., Gounis, M. J., Hacke, W., Liebeskind, D. S., Szikora, I., van Es, Acgm, Brinjikji, W., Doyle, K. M., De Meyer, S. F., De Meyer, S. F. (2019). Histological stroke clot analysis after thrombectomy: Technical aspects and recommendations. <i>International Journal of Stroke</i> , doi: 10.1177/1747493019884527
Publisher	SAGE Publications
Link to publisher's version	<a href="https://doi.org/10.1177/1747493019884527">https://doi.org/10.1177/1747493019884527</a>
Item record	<a href="http://hdl.handle.net/10379/15737">http://hdl.handle.net/10379/15737</a>
DOI	<a href="http://dx.doi.org/10.1177/1747493019884527">http://dx.doi.org/10.1177/1747493019884527</a>

Downloaded 2024-04-26T13:52:15Z

Some rights reserved. For more information, please see the item record link above.



# **Histological stroke clot analysis after thrombectomy: technical aspects and recommendations**

Staessens S.<sup>1</sup>, Fitzgerald S.<sup>2</sup>, Andersson T.<sup>3,4</sup>, Clarençon F.<sup>5</sup>, Denorme F.<sup>1</sup>, Gounis M.J.<sup>6</sup>, Hacke W.<sup>7</sup>, Liebeskind D.S.<sup>8</sup>, Szikora I.<sup>9</sup>, van Es A.C.G.M.<sup>10</sup>, Brinjikji W.<sup>11</sup>, Doyle K.M.<sup>2</sup>, De Meyer S.F.<sup>1</sup> on behalf of the Clot Summit

1 Laboratory for Thrombosis Research, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium

2 CÚRAM-Centre for Research in Medical Devices, National University of Ireland Galway, Galway, Ireland

3 Department of Medical Imaging, AZ Groeninge, Kortrijk, Belgium

4 Department of Neuroradiology, Karolinska University Hospital and Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden

5 Department of Neuroradiology, Pitié-Salpêtrière Hospital, APHP, Paris, France

6 Division of Neuroimaging and Intervention and New England Center for Stroke Research, Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA

7 Department of Neurology, University Hospital Heidelberg, Ruprecht-Karls University, Heidelberg, Germany

8 Neurovascular Imaging Research Core and UCLA Stroke Center, University of California, Los Angeles, CA, USA

9 Department of Neuroradiology, National Institute of Neurosciences, Budapest, Hungary

10 Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center (EMC), Rotterdam, The Netherlands

11 Department of Radiology, Mayo Clinic, Rochester, MN, USA

Correspondence to:

Simon F De Meyer, PhD, Laboratory for Thrombosis Research, KU Leuven Campus Kulak Kortrijk, E.

Sabbelaan 53, 8500 Kortrijk, Belgium, phone: +32-56-246232,

email: [simon.demeyer@kuleuven.be](mailto:simon.demeyer@kuleuven.be)

## **Keywords (4 to 6)**

Stroke, thrombus, thrombectomy, histology, clot

**Word count:** 5030

**Itemized list of tables and figures:**

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Table 1

Supplemental File 1

Supplemental File 2

## **Abstract**

The recent advent of endovascular procedures has created the unique opportunity to collect and analyze thrombi removed from cerebral arteries, instigating a novel subfield in stroke research. Insights into thrombus characteristics and composition could play an important role in ongoing efforts to improve acute ischemic stroke therapy. An increasing number of centers are collecting stroke thrombi. This paper aims at providing guiding information on thrombus handling, procedures and analysis in order to facilitate and standardize this emerging research field.

## **Introduction**

With a global prevalence of 25.7 million strokes per year, stroke is still one of the leading causes of death and sustained disability worldwide. The vast majority of strokes mainly are ischemic, caused by blood thrombi that occlude cerebral blood vessels.(1)

Since the publication of the ‘positive thrombectomy’ trials in 2015, endovascular procedures have emerged to mechanically remove blood thrombi from the cerebral arteries.(2–6) This procedure has created the unique opportunity to provide stroke thrombus material for analysis. Studying thrombus pathology of retrieved material is crucial to improve our understanding, diagnosis, treatment and secondary prevention of acute ischemic stroke.(7) The availability of thrombus material has sparked a novel subfield in stroke research with a rapidly increasing number of studies reporting valuable information using a wide range of techniques and sample sizes. A recent meta-analysis, however, concluded that lack of standardization may limit the generalizability of such studies.(8)

This paper aims to provide recommendations and guidelines on clot collection, processing and analysis in order to facilitate and standardize this emerging research field (Table 1). Supplemental File 1 provides an overview of the most common methods and staining procedures that were used in previous studies.

## **Specimen Retrieval**

Mechanical thrombectomy procedures provide clot material from stroke patients. In general, histopathological analysis of stroke thrombi has been performed predominantly on thrombi retrieved from stent retrievers, although aspiration retrievers are also used to remove thrombi (Supplemental File 1). Processing of the clot starts from the moment of clot retrieval. After retraction of the thrombectomy device, the retrieved clot material is gently removed from the device and transferred into saline (Figure 1a). It is recommended to use non-heparinized

saline or saline free of other anticoagulants to prevent interference with the clot. For stent retrievers, the thrombus is entangled within the stent and needs to be carefully removed from the device using for example forceps. Depending on the fragility of the clot, it is either collected in one piece or in multiple fragments. For aspiration devices, clot material, together with aspirated blood, is flushed from the device into a collection container with saline. Since the aspirated blood can lead to further clot growth, isolated clots have to be immediately transferred into a different container with fresh saline until fixation.

Multiple procedural passes can give several fragments of clot material. Typically, all collected material from all passes in one patient is collected, processed and labeled together as one and the same clot. If clot analysis per pass is desired, clot material from each pass can be processed separately (Figure 1b). Such approach can yield useful "per pass" information and thus insight into the composition of difficult to remove clots and clot fragments. It however, significantly increases the workload involved.

Removal of the clot from the retriever allows for easy pooling of collected material and efficient further processing of the collected clot material. However, if the interaction between the clot and the stent struts are to be examined, the complete stent with the retrieved clot can be further processed as a whole.

## **Fixation**

After collection and rinsing of the clot in saline, the specimen needs to be fixated to preserve its structure. Although immediate fixation after thrombus retrieval and rinsing is recommended, our experience is that thrombi can be stored in saline up to 24 hours without the occurrence of significant morphological changes in the thrombus. This time window allows protocol flexibility for thrombi that cannot be fixated immediately. For fixation, a solution of 10% formalin (3.7% formaldehyde) is routinely used (Supplemental File 1). If electron microscopy

analyses are required, an appropriate fixation method for the different electron microscopy techniques is to be applied. We recommend fixation for 24 hours. After fixation, it is recommended to start the embedding process. Longer fixation times are possible but can affect subsequent staining procedures by irreversibly masking antigens of interest. Our experience is that fixation protocols lasting longer than one week increase the autofluorescence of clot material, and we recommend that samples are stored in 10% formalin for no longer than one month, if they cannot be further processed after 24 hours of fixation. If further processing of the clot is not feasible at the site of thrombectomy, the clot can be transported a sealed container containing 10% formalin or saline for further processing. In addition, if mechanical analyses on the clot are to be performed, fixation should be avoided.

### **Paraffin embedding**

After fixation, samples are embedded in paraffin. This results in good preservation of tissue morphology and allows easy long-term storage of the embedded clot material at room temperature until sectioning. We recommend standard dehydration and paraffin embedding procedures, including sequential dehydration via increasing concentrations of ethanol (70%, 80%, 95%, 3 x 100%), followed by two immersions in xylene, and two immersions in paraffin. We recommend that the clot is embedded such that the largest cross-sectional area will be achieved, typically along the length of the thrombus. (Figure 1c). All retrieved material from one patient can be embedded in one block, or material from each pass can be kept separate and embedded in separate blocks if per pass information is desired. Paraffin blocks containing stroke thrombi can be easily and safely transported to other research centers for further study.

### **Sectioning**

In previous studies, section thickness has varied from 2 to 10  $\mu\text{m}$  (Supplemental File 1) but a thickness of 4 to 5  $\mu\text{m}$  is mainly used. Thinner sections can minimize the complication of several structures lying on top of each other and facilitate ease of quantification of main components by image analysis software, but require more skill to section. We recommend a thickness of 3 to 5  $\mu\text{m}$  as optimum.

The paraffin block should be trimmed until a full-face section of the clot material is reached and serial sections taken from this point. Depending on the size of the clot fragment, multiple serial sections can be added to each slide. The total number of sections taken will depend on the number of tests and replicates being performed.

It is our experience that the composition of embedded thrombus does not vary considerably from superior to inferior aspect, suggesting that the whole thrombus may not need to be sectioned, depending on the research question. We suggest that, for standard analyses, the first 20 whole-face sections may be sufficient (see further information on intra-thrombus variability).

## **Staining**

After sectioning, thrombus composition can be studied via various staining procedures. Depending on the component of interest, hematoxylin and eosin staining (H&E), Martius Scarlet Blue staining (MSB) and immunohistochemistry procedures have been typically used. A detailed literature overview of histological procedures can be found in Supplemental File 1. Most studies have been focusing on the presence of red blood cells, fibrin, platelets and white blood cells (Supplemental File 1). However, different staining methods with various degrees of specificity have been used per composition marker, which can impede easy comparison of the results. Quantification of thrombus composition is preferably based on staining procedures that have good specificity.

Classical H&E is mostly used to visualize the general overall structure of the thrombus. Staining with H&E stains acidophilic components (e.g. cytoplasm, fibrin) pink and basophilic components (e.g. nuclei) blue (Figure 2a). Although not very specific, we do recommend including the use of H&E as a quick and easy procedure for general purpose but not for quantitative determination of thrombus composition due to a lack of specificity. Instead, we recommend Martius Scarlet Blue (MSB) staining for quantification of RBC and fibrin content (Figure 2b). MSB staining allows for the selective demonstration of fibrin, which is stained red using a crystal scarlet solution and of RBC that are stained yellow using a Martius yellow solution. Although not common in stroke thrombi, collagen appears blue with a methyl blue solution. The distinct yellow and red colors are easy to discriminate and allows for a quick, cost-effective and selective determination of RBC and fibrin, which is practical for large-scale, high-throughput studies.

Besides RBC and fibrin, we believe that three other components are of general interest and should become standard for thrombus analysis. These are white blood cells (WBC), platelets and von Willebrand factor (VWF), which each are best visualized through immunohistochemical staining procedures (Figure 2c-e).

For platelets and white blood cells, antibodies against various epitopes are available but the consensus is that CD42 and CD45 are the most specific epitopes for platelets and white blood cells respectively. Commercial antibodies against VWF are available and give reliable results on VWF content.<sup>(9)</sup> Additional antibodies, e.g. against different subsets of leukocytes or other proteins of interest, can be added. Immunohistochemical stains are typically based on the precipitation of 3,3'-diaminobenzidine (DAB), a substrate with a brown color in combination with a hematoxylin counterstain. In our hands, this method often gives unsatisfactory results because the specific brown staining of the antigen is not easily discriminated from unstained red blood cells that also have a brownish color (Figure 3a). In order to perform accurate color-

based segmentation quantification, we recommend the use of other coloured substrates, such as a purple-colored substrate in combination with a methyl green counterstain (Figure 3b).

## **Analysis**

Besides uniform staining procedures, standardized quantitation algorithms to calculate thrombus composition are also important to improve generalizability in the field. In the past, both manual quantifications and color-based segmentation analysis have been used (Supplemental File 1). Manual quantification is primarily used to count the number of cells per mm<sup>2</sup>, but can be labor-intensive, especially in large-scale studies. Computational color-based segmentation analysis provides a better way to obtain quantitative information on thrombus composition (RBC, fibrin, WBC, platelets and VWF). Various software programs such as ImageJ, Adobe Photoshop and Orbit Image Analyzer are available to apply thresholds for color and good selective quantification of specific colors/components (Figure 4a, b and c).(10–13) These software-based analyses provide data in a partially automated manner and produce quantitative results (% of total thrombus section area) that are easy to compare across multiple studies/centers. In our experience, software-based computational analysis produces thrombus composition data that strongly correlates with manual quantification methods. The very considerable time saving makes software-based analysis a very attractive option.

A key question performing quantitative analysis is whether intra-thrombus heterogeneity, and thus the location of the section within the thrombus, affects quantitative conclusions. Macroscopically, thrombi appear heterogeneous in size, color, shape and fragmentation. Most quantitative studies have taken the data obtained from only one section per thrombus as representative for the whole thrombus. To better understand intra-thrombus variability, we completely sectioned 8 thrombi from ischemic stroke patients and analyzed multiple sections throughout the thrombus (approximately 75  $\mu$ m apart). We used MSB staining

to quantify the presence of fibrin and RBC on each section (Figure 4). As expected, in each of the 8 thrombi, some degree of intra-thrombus variation is observed throughout the thrombus but measurements from different sections of one thrombus cluster around the mean value with an acceptable spread. Sectioning the whole thrombus to analyze multiple sections throughout the clot might give a more accurate of the mean value of the composition but is not practical for larger studies. Partial sectioning of the thrombus, combined with analysis of only one to three sections reduces the workload and still provides a good estimate of thrombus composition, as shown in Figure 5. A similar approach was used to assess the intra-thrombus variability of the presence of VWF and platelets (via immunostaining) in 3 thrombi, yielding similar results (data not shown). Based on our experience, we recommend the use of one thrombus section per staining to estimate thrombus composition in large-scale studies, as large sample sizes will compensate the minor intra-thrombus variability. For small sample size studies and testing of novel markers, we do recommend the use of three sections per staining to account for potential intra-thrombus variability (Figure 5a-h).

### **Collection of patient data**

Understanding thrombus composition has a number of potential implications for clinical treatment. Despite recent advances in endovascular procedures, still 20% of thrombi are not retrievable.<sup>(14)</sup> Although these thrombi are not available for analysis, linking thrombus composition to both clinical and procedural information can provide useful insights that can guide stroke therapy. For example, fibrin-rich thrombi have been associated with an increased coefficient of friction, a higher number of retraction maneuvers and increased thrombus extraction times.<sup>(15–17)</sup> Evidently, linking thrombus composition with other clinical aspects such as stroke etiology and stroke outcome can provide crucial information. Therefore, when collecting thrombi for histological analysis, we recommend keeping a general data abstraction

form that includes both clinical and procedural information per thrombus. To prevent a selection bias, we also recommend collecting the clinical information of those thrombi that are not retrievable (TICI 0 or where no thrombus material was found in the stent). Supplemental file 2 provides an example of a data abstraction form that contains the 'must-have' data. So far, thrombus composition studies have reported a wide variety of clinical and procedural information with a particular focus on stroke severity (National Institute of Health Stroke Scale; NIHSS), recanalization success (Thrombolysis in Cerebral Infarction Scale; TICI), stroke etiology (Trial of Org 10172 in Acute Stroke Treatment; TOAST), functional outcome (modified Ranking Score; mRS) and procedural information (amount of retraction maneuvers and thrombus extraction time). In addition, we recommend the collection of complete blood counts as well as other clinical parameters such as for example comorbidities in order to have a detailed clinical history of the patient. (Supplemental File 2). Standardization of the 'must-have' information (Supplemental file 2) will increase generalizability among studies. Record keeping of this information must be embedded in the clinical standard operating procedures of the thrombectomy unit. The move towards the development of national stroke registries in Europe will also facilitate correlation between thrombus composition and clinical information.

### **Limitations**

The analysis of thrombi retrieved from ischemic stroke patients has some limitations that are worth consideration. Rolling, movement or fragmentation of the thrombus in the thrombectomy device during the extraction procedure hinders exact knowledge on the original orientation of the thrombus in the occluded blood vessel. Importantly, only those thrombi that did not dissolve spontaneously or after administration of tissue plasminogen activator (t-PA) and thrombi that could be successfully retrieved via thrombectomy are accessible for study. This impedes the assessment of thrombi that were t-PA susceptible or thrombectomy resistant.

Nevertheless, specific attention to those thrombi that were difficult to retrieve could provide useful information on thrombi that are impossible to retrieve.

## **Conclusion**

In this rapidly evolving field, best practices for thrombus characterization and data collection will become important. This effort will maximize the generalizability of the results to make important inroads with respect to discrimination of stroke etiology and informed secondary prevention measures, as well as optimizing the thrombectomy procedure to maximize clinical outcomes.

## **Acknowledgements**

The authors have no other acknowledgements to report.

## **Funding**

This work was supported by research grants to S.F.D.M. from the Fonds voor Wetenschappelijk Onderzoek – Vlaanderen (FWO) (research grants G.0A86.13, G.0785.17 and 1509216N), the KU Leuven (OT/14/099 and ISP/14/02L2), the Queen Elisabeth Medical Foundation and by the European Union's Horizon 2020 Research and Innovation Program INSIST under grant agreement No 777072. F.D. is a postdoctoral fellow of the FWO (FWO, 12U7818N). This work is also supported by a research grant to KD from Science Foundation Ireland, co-funded under the European Regional Development fund under Grant Number 13/RC/2073 and Cerenovus.

## **Conflict of Interest**

The author(s) declared the following potential conflict of interest with respect to the research, authorship, and/or publication of this article: F.C. declares conflict of interest with Medtronic, Guerbet, Balt Extrusion (speaker honorarium), Codman Neurovascular (core lab). W.H. declares honoraria from Cerenovus for participation in advisory boards and steering

committees. T.A. declares consultancy for Ablynx, Amnis Therapeutics, Anaconda, Cerenovus, Medtronic and Rapid Medical. W.B. has received research grants from the National Institute of Health, has an Owership Interest in Marblehead Medical LLC and has received research support from Johnson & Johnson. A.C.G.M.v.E, D.S.L., F.D., I.S., K.M.D., M.J.G., S.F., S.F.D.M, S.S. have no conflict of interest to declare.

### **Ethical approval**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study under the approval of the AZ Groeninge Hospital ethical committee (AZGS2015065). No animal experiments were performed in this study.

## References

1. Benjamin, E. J., Blaha, M. J., Chiuve, S. E., et al. (2017) Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. *Circulation*. **135**, e146–e603
2. Berkhemer, O. A., Fransen, P. S. S., Beumer, D., et al. (2015) A randomized trial of intraarterial treatment for acute ischemic stroke. *N. Engl. J. Med.* **372**, 11–20
3. Campbell, B. C. V, Mitchell, P. J., Kleinig, T. J., et al. (2015) Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N. Engl. J. Med.* **372**, 1009–1018
4. Goyal, M., Demchuk, A. M., Menon, B. K., et al. (2015) Randomized assessment of rapid endovascular treatment of ischemic stroke. *New Engl J Med.* **372**, 1019–1030
5. Saver, J. L., Goyal, M., Bonafé, A., et al. (2015) Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N. Engl. J. Med.* **372**, 2285–2295
6. Jovin, T. G., Chamorro, A., Cobo, E., et al. (2015) Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke. *New Engl J Med.* **372**, 2296–2306
7. De Meyer, S. F., Andersson, T., Baxter, B., et al. (2017) Analyses of thrombi in acute ischemic stroke: A consensus statement on current knowledge and future directions. *Int J Stroke.* **12**, 606–614
8. Brinjikji, W., Duffy, S., Burrows, A., et al. (2017) Correlation of imaging and histopathology of thrombi in acute ischemic stroke with etiology and outcome: a systematic review. *J. Neurointerv. Surg.* **9**, 529–534
9. Denorme, F., Langhauser, F., Desender, L., et al. (2016) ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. *Blood.* **127**, 2337–2345
10. Prasad, K., and Prabhu, G. K. (2012) Image analysis tools for evaluation of microscopic views of immunohistochemically stained specimen in medical research-a

- review. *J Med Syst.* **36**, 2621–2631
11. Lehr, H. A., van der Loos, C. M., Teeling, P., and Gown, A. M. (1999) Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. *J. Histochem. Cytochem.* **47**, 119–126
  12. Zhou, Y., Ru, G. Q., Yan, R., et al. (2017) An Inexpensive Digital Image Analysis Technique for Liver Fibrosis Quantification in Chronic Hepatitis B Patients. *Ann Hepatol.* **16**, 881–887
  13. Arena, E. T., Rueden, C. T., Hiner, M. C., et al. (2017) Quantitating the cell: turning images into numbers with ImageJ. *Wiley Interdiscip Rev Dev Biol.* **6**, e260
  14. Yoo, A. J., and Andersson, T. (2017) Thrombectomy in Acute Ischemic Stroke: Challenges to Procedural Success. *J Stroke.* **19**, 121–130
  15. Maekawa, K., Shibata, M., Nakajima, H., et al. (2018) Erythrocyte-Rich Thrombus Is Associated with Reduced Number of Maneuvers and Procedure Time in Patients with Acute Ischemic Stroke Undergoing Mechanical Thrombectomy. *Cerebrovasc Dis Extra.* **8**, 39–49
  16. Boeckh-Behrens, T., Schubert, M., Förchler, A., et al. (2016) The Impact of Histological Clot Composition in Embolic Stroke. *Clin. Neuroradiol.* **26**, 189–197
  17. Gunning, G. M., Kevin, M., Mirza, M., et al. (2018) Clot friction variation with fibrin content; implications for resistance to thrombectomy. *J Neurointerv Surg.* **10**, 34–38
  18. Marder, V. J., Chute, D. J., Starkman, S., et al. (2006) Analysis of Thrombi Retrieved From Cerebral Arteries of Patients With Acute Ischemic Stroke. *Stroke.* **37**, 2086–2093
  19. Almekhlafi, M. A., Hu, W. Y., Hill, M. D., and Auer, R. N. (2008) Calcification and endothelialization of thrombi in acute stroke. *Ann. Neurol.* **64**, 344–348
  20. Liebeskind, D. S., Sanossian, N., Yong, W. H., et al. (2011) CT and MRI early vessel signs reflect clot composition in acute stroke. *Stroke.* **42**, 1237–1243

21. Chueh, J. Y., Wakhloo, A. K., Hendricks, G. H., et al. (2011) Mechanical characterization of thromboemboli in acute ischemic stroke and laboratory embolus analogs. *Am. J. Neuroradiol.* **32**, 1237–1244
22. Singh, P., Doostkam, S., Reinhard, M., et al. (2013) Immunohistochemical analysis of thrombi retrieved during treatment of acute ischemic stroke: does stent-retriever cause intimal damage? *Stroke.* **44**, 1720–1722
23. Niesten, J. M., van der Schaaf, I. C., van Dam, L., et al. (2014) Histopathologic composition of cerebral thrombi of acute stroke patients is correlated with stroke subtype and thrombus attenuation. *PLoS One.* **9**, e88882
24. Simons, N., Mitchell, P., Dowling, R., et al. (2015) Thrombus composition in acute ischemic stroke: a histopathological study of thrombus extracted by endovascular retrieval. *J Neuroradiol.* **42**, 86–92
25. Kim, S. K., Yoon, W., Kim, T. S., et al. (2015) Histologic Analysis of Retrieved Clots in Acute Ischemic Stroke: Correlation with Stroke Etiology and Gradient-Echo MRI. *Am. J. Neuroradiol.* **36**, 1756–1762
26. Sallustio, F., Arno, N., Legge, D. S., et al. (2015) Histological Features of Intracranial Thrombo-Emboli Predict Response to Endovascular Therapy for Acute Ischemic Stroke. *J. Neurol. Disord. Stroke.* **3**, 1105–1110
27. Boeckh-Behrens, T., Kleine, J. F., Zimmer, C., et al. (2016) Thrombus Histology Suggests Cardioembolic Cause in Cryptogenic Stroke. *Stroke.* **47**, 1864–1871
28. Dargazanli, C., Rigau, V., Eker, O., et al. (2016) High CD3+ Cells in Intracranial Thrombi Represent a Biomarker of Atherothrombotic Stroke. *PLoS One.* **11**, e0154945
29. Ahn, S., Hong, R., Choo, I., et al. (2016) Histologic features of acute thrombi retrieved from stroke patients during mechanical reperfusion therapy. *Int. J. Stroke.* **11**, 1036–1044

30. Qureshi, A. I., Qureshi, M. H., Lobanova, I., et al. (2016) Histopathological Characteristics of IV Recombinant Tissue Plasminogen-Resistant Thrombi in Patients with Acute Ischemic Stroke. *J. Vasc. Interv. Neurol.* **8**, 38–45
31. Schuhmann, M. K., Gunreben, I., Kleinschnitz, C., and Kraft, P. (2016) Immunohistochemical Analysis of Cerebral Thrombi Retrieved by Mechanical Thrombectomy from Patients with Acute Ischemic Stroke. *Int. J. Mol. Sci.* **17**, 298
32. Hashimoto, T., Hayakawa, M., Funatsu, N., et al. (2016) Histopathologic Analysis of Retrieved Thrombi Associated With Successful Reperfusion After Acute Stroke Thrombectomy. *Stroke.* **47**, 3035–3037
33. Laridan, E., Denorme, F., Desender, L., et al. (2017) Neutrophil extracellular traps in ischemic stroke thrombi. *Ann. Neurol.* **82**, 223–232
34. Maegerlein, C., Friedrich, B., Berndt, M., et al. (2017) Impact of histological thrombus composition on preinterventional thrombus migration in patients with acute occlusions of the middle cerebral artery. *Interv Neuroradiol.* **24**, 1591019917733733
35. Sporns, P. B., Hanning, U., Schwindt, W., et al. (2017) Ischemic Stroke: What Does the Histological Composition Tell Us About the Origin of the Thrombus? *Stroke.* **48**, 2206–2210
36. Boeckh-Behrens, T., Kleine, J., Kaesmacher, J., et al. (2017) The CD31 molecule: a possible neuroprotective agent in acute ischemic stroke? *Thromb J.* **15**, 11
37. Francisco, H.-F., Laura, R.-B., Jorge, G.-G., et al. (2017) Histopathological and Bacteriological Analysis of Thrombus Material Extracted During Mechanical Thrombectomy in Acute Stroke Patients. *Cardiovasc Interv. Radiol.* **40**, 1851–1860
38. Kaesmacher, J., Boeckh-Behrens, T., Simon, S., et al. (2017) Risk of Thrombus Fragmentation during Endovascular Stroke Treatment. *Am J Neuroradiol.* **38**, 991–998
39. Berndt, M., Friedrich, B., Maegerlein, C., et al. (2018) Thrombus Permeability in


- Admission Computed Tomographic Imaging Indicates Stroke Pathogenesis Based on Thrombus Histology. *Stroke*. **49**, 2674–2682
40. Sporns, P. B., Hanning, U., Schwindt, W., et al. (2017) Ischemic Stroke: Histological Thrombus Composition and Pre-Interventional CT Attenuation Are Associated with Intervention Time and Rate of Secondary Embolism. *Cerebrovasc. Dis.* **44**, 344–350
41. Krajíčková, D., Krajina, A., Šteiner, I., et al. (2017) Fibrin Clot Architecture in Acute Ischemic Stroke Treated With Mechanical Thrombectomy With Stent-Retrievers - Cohort Study. *Circ. J.* **82**, CJ-17-0375
42. Choi, M., Park, G., Lee, J., et al. (2018) Erythrocyte Fraction Within Retrieved Thrombi Contributes to Thrombolytic Response in Acute Ischemic Stroke. *Stroke*. **49**, 652–659
43. Shin, J. W., Jeong, H. S., Kwon, H.-J. J., et al. (2018) High red blood cell composition in clots is associated with successful recanalization during intra-arterial thrombectomy. *PLoS One*. **13**, e0197492
44. Prochazka, V., Jonszta, T., Czerny, D., et al. (2018) The Role of von Willebrand Factor, ADAMTS13, and Cerebral Artery Thrombus Composition in Patient Outcome Following Mechanical Thrombectomy for Acute Ischemic Stroke. *Med. Sci. Monit.* **24**, 3929–3945
45. Ducroux, C., Di Meglio, L., Loyau, S., et al. (2018) Thrombus Neutrophil Extracellular Traps Content Impair tPA-Induced Thrombolysis in Acute Ischemic Stroke. *Stroke*. **49**, 754–757
46. Berndt, M., Prothmann, S., Maegerlein, C., et al. (2018) Artificial Stroke Clots: How Wide is the Gap to the Real World? *World Neurosurg.* **110**, e90–e99

**Table 1: Specific recommendations**


<b>Processing step</b>	<b>Recommendation</b>	<b>Remarks</b>
<b>Retrieval</b>	<ul style="list-style-type: none"> <li>• gently remove clot material from stent retriever and transfer to non-heparinized saline</li> <li>• flush clot from aspiration device and transfer clot material to saline</li> <li>• store in saline at 4 C° for max. 24 h</li> </ul>	
<b>Fixation</b>	<ul style="list-style-type: none"> <li>• fixate thrombus material in 10% formalin (3.7% formaldehyde) for 24 h</li> </ul>	
<b>Paraffin embedding</b>	<ul style="list-style-type: none"> <li>• embed in paraffin via standard dehydration steps</li> <li>• embed clot so that maximum cross section will be achieved when sectioning</li> </ul>	
<b>Sectioning</b>	<ul style="list-style-type: none"> <li>• prepare sections of 3-5 µm thick</li> </ul>	A total of 20 sections is typically sufficient to obtain a representative composition analysis
<b>Staining</b>	<ul style="list-style-type: none"> <li>• stain sections with               <ul style="list-style-type: none"> <li>○ H&amp;E (general structure)</li> <li>○ MSB (fibrin, RBCs)</li> <li>○ anti-CD42 antibody (platelets)</li> <li>○ anti-CD45 antibody (WBC)</li> <li>○ anti-VWF antibody (VWF)</li> </ul> </li> </ul>	MSB staining can be combined with a hematoxylin counterstain to visualize nucleated cells

<b>Quantitative analysis</b>	<ul style="list-style-type: none"><li>• quantify the presence of clot components via computational color-based segmentation analysis</li><li>• analysis of one section per thrombus for each staining is sufficient in large scale studies. For small scale studies, three sections, from different parts throughout the thrombus can be recommended</li><li>• calculate for each component positive area as % of total thrombus section area</li></ul>	

**Figures**




**Figure 1:** (a) Thrombi retrieved after thrombectomy, prior to fixation, appear heterogeneous in size, color and fragmentation. Thrombi can also be analyzed in a per pass manner. (b) Thrombi retrieved can display marked heterogeneity per pass. (c) After fixation, thrombi are processed and embedded in paraffin blocks.




**Figure 2:** Recommended histological staining procedures for thrombi retrieved from acute ischemic stroke thrombi. Consecutive thrombus sections were stained with (a) classical H&E, (b) MSB and antibodies against (c) CD42b (platelets), (d) VWF and (e) CD45 (leukocytes).


Left panels (scale = 2 mm) represent an overview of the complete thrombus section. Right panels (scale = 100  $\mu$ m) show a magnification. Classical H&E provides a general overview of the thrombus. On MSB staining, red areas show the presence of fibrin, whereas red blood cells are depicted in yellow. Positive signal in an immunohistochemical staining (c-e) is depicted in purple, red blood cells and nuclei are depicted in light brown and green respectively.



**Figure 3:** Comparison between various immunohistochemical substrate colors in stroke thrombi. (a) Development of a VWF staining using DAB (brown) with a hematoxylin counterstain. (b) Development of a VWF staining using a purple substrate with a methyl green counterstain. The purple substrate allows for better discrimination between positive staining and unstained red blood cells (light brown).



**Figure 4:** (a) Quantitative example of an MSB staining using color-based segmentation analysis in Image J. In panel A, an image of the staining before application of a threshold is shown (left), as well as the same image after applying a threshold for fibrin (middle) and for red blood cells (right). (b) Quantitative example of an MSB staining using color-based machine learning techniques in Orbit Image Analyzer before (left) and after (right) software analysis. (c) Quantitative example of a VWF staining using color-based segmentation analysis in Image J before (left) and after (right) applying and selecting the color-based segmentation.



**Figure 5:** (a-h) Intra-thrombus variability measured in 8 stroke thrombi stained with MSB and analyzed for the amount of fibrin and red blood cells. Percentages of fibrin and red blood cells

in the thrombus are shown for all sections analyzed throughout the entire thrombus (1) (approximately every 75  $\mu\text{m}$ , each data point represents one section), or when only three sections, located at the end of the first, second and third quarter of the thrombus, were analyzed, representing a scenario in which not all sections are stained (2) or when the first three sections that are 75  $\mu\text{m}$  apart were analyzed, representing a scenario in which only the first part of the thrombus is sectioned (3).





1. Benjamin, E. J., Blaha, M. J., Chiuve, S. E., et al. (2017) Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. *Circulation*. **135**, e146–e603
2. Berkhemer, O. A., Fransen, P. S. S., Beumer, D., et al. (2015) A randomized trial of intraarterial treatment for acute ischemic stroke. *N. Engl. J. Med.* **372**, 11–20
3. Campbell, B. C. V, Mitchell, P. J., Kleinig, T. J., et al. (2015) Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N. Engl. J. Med.* **372**, 1009–1018
4. Goyal, M., Demchuk, A. M., Menon, B. K., et al. (2015) Randomized assessment of rapid endovascular treatment of ischemic stroke. *New Engl J Med.* **372**, 1019–1030
5. Saver, J. L., Goyal, M., Bonafé, A., et al. (2015) Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N. Engl. J. Med.* **372**, 2285–2295
6. Jovin, T. G., Chamorro, A., Cobo, E., et al. (2015) Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke. *New Engl J Med.* **372**, 2296–2306
7. De Meyer, S. F., Andersson, T., Baxter, B., et al. (2017) Analyses of thrombi in acute ischemic stroke: A consensus statement on current knowledge and future directions. *Int J Stroke*. **12**, 606–614
8. Brinjikji, W., Duffy, S., Burrows, A., et al. (2017) Correlation of imaging and histopathology of thrombi in acute ischemic stroke with etiology and outcome: a systematic review. *J. Neurointerv. Surg.* **9**, 529–534
9. Denorme, F., Langhauser, F., Desender, L., et al. (2016) ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice.

*Blood.* **127**, 2337–2345

10. Prasad, K., and Prabhu, G. K. (2012) Image analysis tools for evaluation of microscopic views of immunohistochemically stained specimen in medical research-a review. *J Med Syst.* **36**, 2621–2631
11. Lehr, H. A., van der Loos, C. M., Teeling, P., and Gown, A. M. (1999) Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. *J. Histochem. Cytochem.* **47**, 119–126
12. Zhou, Y., Ru, G. Q., Yan, R., et al. (2017) An Inexpensive Digital Image Analysis Technique for Liver Fibrosis Quantification in Chronic Hepatitis B Patients. *Ann Hepatol.* **16**, 881–887
13. Arena, E. T., Rueden, C. T., Hiner, M. C., et al. (2017) Quantitating the cell: turning images into numbers with ImageJ. *Wiley Interdiscip Rev Dev Biol.* **6**, e260
14. Yoo, A. J., and Andersson, T. (2017) Thrombectomy in Acute Ischemic Stroke: Challenges to Procedural Success. *J Stroke.* **19**, 121–130
15. Maekawa, K., Shibata, M., Nakajima, H., et al. (2018) Erythrocyte-Rich Thrombus Is Associated with Reduced Number of Maneuvers and Procedure Time in Patients with Acute Ischemic Stroke Undergoing Mechanical Thrombectomy. *Cerebrovasc Dis Extra.* **8**, 39–49
16. Boeckh-Behrens, T., Schubert, M., Förschler, A., et al. (2016) The Impact of Histological Clot Composition in Embolic Stroke. *Clin. Neuroradiol.* **26**, 189–197
17. Gunning, G. M., Kevin, M., Mirza, M., et al. (2018) Clot friction variation with fibrin content; implications for resistance to thrombectomy. *J Neurointerv Surg.* **10**, 34–38
18. Marder, V. J., Chute, D. J., Starkman, S., et al. (2006) Analysis of Thrombi Retrieved From Cerebral Arteries of Patients With Acute Ischemic Stroke. *Stroke.* **37**, 2086–2093

19. Almekhlafi, M. A., Hu, W. Y., Hill, M. D., and Auer, R. N. (2008) Calcification and endothelialization of thrombi in acute stroke. *Ann. Neurol.* **64**, 344–348
20. Liebeskind, D. S., Sanossian, N., Yong, W. H., et al. (2011) CT and MRI early vessel signs reflect clot composition in acute stroke. *Stroke.* **42**, 1237–1243
21. Chueh, J. Y., Wakhloo, A. K., Hendricks, G. H., et al. (2011) Mechanical characterization of thromboemboli in acute ischemic stroke and laboratory embolus analogs. *Am. J. Neuroradiol.* **32**, 1237–1244
22. Singh, P., Doostkam, S., Reinhard, M., et al. (2013) Immunohistochemical analysis of thrombi retrieved during treatment of acute ischemic stroke: does stent-retriever cause intimal damage? *Stroke.* **44**, 1720–1722
23. Niesten, J. M., van der Schaaf, I. C., van Dam, L., et al. (2014) Histopathologic composition of cerebral thrombi of acute stroke patients is correlated with stroke subtype and thrombus attenuation. *PLoS One.* **9**, e88882
24. Simons, N., Mitchell, P., Dowling, R., et al. (2015) Thrombus composition in acute ischemic stroke: a histopathological study of thrombus extracted by endovascular retrieval. *J Neuroradiol.* **42**, 86–92
25. Kim, S. K., Yoon, W., Kim, T. S., et al. (2015) Histologic Analysis of Retrieved Clots in Acute Ischemic Stroke: Correlation with Stroke Etiology and Gradient-Echo MRI. *Am. J. Neuroradiol.* **36**, 1756–1762
26. Sallustio, F., Arno, N., Legge, D. S., et al. (2015) Histological Features of Intracranial Thrombo-Emboli Predict Response to Endovascular Therapy for Acute Ischemic Stroke. *J. Neurol. Disord. Stroke.* **3**, 1105–1110
27. Boeckh-Behrens, T., Kleine, J. F., Zimmer, C., et al. (2016) Thrombus Histology Suggests Cardioembolic Cause in Cryptogenic Stroke. *Stroke.* **47**, 1864–1871

28. Dargazanli, C., Rigau, V., Eker, O., et al. (2016) High CD3+ Cells in Intracranial Thrombi Represent a Biomarker of Atherothrombotic Stroke. *PLoS One*. **11**, e0154945
29. Ahn, S., Hong, R., Choo, I., et al. (2016) Histologic features of acute thrombi retrieved from stroke patients during mechanical reperfusion therapy. *Int. J. Stroke*. **11**, 1036–1044
30. Qureshi, A. I., Qureshi, M. H., Lobanova, I., et al. (2016) Histopathological Characteristics of IV Recombinant Tissue Plasminogen-Resistant Thrombi in Patients with Acute Ischemic Stroke. *J. Vasc. Interv. Neurol*. **8**, 38–45
31. Schuhmann, M. K., Gunreben, I., Kleinschnitz, C., and Kraft, P. (2016) Immunohistochemical Analysis of Cerebral Thrombi Retrieved by Mechanical Thrombectomy from Patients with Acute Ischemic Stroke. *Int. J. Mol. Sci*. **17**, 298
32. Hashimoto, T., Hayakawa, M., Funatsu, N., et al. (2016) Histopathologic Analysis of Retrieved Thrombi Associated With Successful Reperfusion After Acute Stroke Thrombectomy. *Stroke*. **47**, 3035–3037
33. Laridan, E., Denorme, F., Desender, L., et al. (2017) Neutrophil extracellular traps in ischemic stroke thrombi. *Ann. Neurol*. **82**, 223–232
34. Maegerlein, C., Friedrich, B., Berndt, M., et al. (2017) Impact of histological thrombus composition on preinterventional thrombus migration in patients with acute occlusions of the middle cerebral artery. *Interv Neuroradiol*. **24**, 1591019917733733
35. Sporns, P. B., Hanning, U., Schwindt, W., et al. (2017) Ischemic Stroke: What Does the Histological Composition Tell Us About the Origin of the Thrombus? *Stroke*. **48**, 2206–2210
36. Boeckh-Behrens, T., Kleine, J., Kaesmacher, J., et al. (2017) The CD31 molecule: a possible neuroprotective agent in acute ischemic stroke? *Thromb J*. **15**, 11
37. Francisco, H.-F., Laura, R.-B., Jorge, G.-G., et al. (2017) Histopathological and Bacteriological Analysis of Thrombus Material Extracted During

- Mechanical Thrombectomy in Acute Stroke Patients. *Cardiovasc Interv. Radiol.* **40**, 1851–1860
38. Kaesmacher, J., Boeckh-Behrens, T., Simon, S., et al. (2017) Risk of Thrombus Fragmentation during Endovascular Stroke Treatment. *Am J Neuroradiol.* **38**, 991–998
  39. Berndt, M., Friedrich, B., Maegerlein, C., et al. (2018) Thrombus Permeability in Admission Computed Tomographic Imaging Indicates Stroke Pathogenesis Based on Thrombus Histology. *Stroke.* **49**, 2674–2682
  40. Sporns, P. B., Hanning, U., Schwindt, W., et al. (2017) Ischemic Stroke: Histological Thrombus Composition and Pre-Interventional CT Attenuation Are Associated with Intervention Time and Rate of Secondary Embolism. *Cerebrovasc. Dis.* **44**, 344–350
  41. Krajíčková, D., Krajina, A., Šteiner, I., et al. (2017) Fibrin Clot Architecture in Acute Ischemic Stroke Treated With Mechanical Thrombectomy With Stent-Retrievers - Cohort Study. *Circ. J.* **82**, CJ-17-0375
  42. Choi, M., Park, G., Lee, J., et al. (2018) Erythrocyte Fraction Within Retrieved Thrombi Contributes to Thrombolytic Response in Acute Ischemic Stroke. *Stroke.* **49**, 652–659
  43. Shin, J. W., Jeong, H. S., Kwon, H.-J. J., et al. (2018) High red blood cell composition in clots is associated with successful recanalization during intra-arterial thrombectomy. *PLoS One.* **13**, e0197492
  44. Prochazka, V., Jonszta, T., Czerny, D., et al. (2018) The Role of von Willebrand Factor, ADAMTS13, and Cerebral Artery Thrombus Composition in Patient Outcome Following Mechanical Thrombectomy for Acute Ischemic Stroke. *Med. Sci. Monit.* **24**, 3929–3945
  45. Ducroux, C., Di Meglio, L., Loyau, S., et al. (2018) Thrombus Neutrophil Extracellular Traps Content Impair tPA-Induced Thrombolysis in Acute Ischemic Stroke. *Stroke.* **49**, 754–757
  46. Berndt, M., Prothmann, S., Maegerlein, C., et al. (2018) Artificial Stroke Clots: How Wide is the Gap to the Real World? *World Neurosurg.* **110**, e90–



## Supplemental File 2: Clot data collection sheet

### Sample Details

Thrombus sample code: \_\_\_\_\_ Procedure date: \_\_\_\_\_

Hospital + treating physician: \_\_\_\_\_

Age: \_\_\_\_\_ Gender:  Male  Female

### Basic Information

rt-PA:  None  IA  IV

Occlusion location: \_\_\_\_\_ Hyperdense artery sign on CT:  Yes  No

Mean clot HU (if available): \_\_\_\_\_ Max clot HU (if available): \_\_\_\_\_

NIHSS admission: \_\_\_\_\_ NIHSS discharge: \_\_\_\_\_

Discharge mRS: \_\_\_\_\_ 90 day mRS: \_\_\_\_\_

Stroke etiology:  Cardioembolic  Large-artery atherosclerotic  Unknown  Other

Specify if other: \_\_\_\_\_

Final TICI score:  0  1  2a  2b  3

List of thrombectomy devices used:

---

---

---

Amount of passes to achieve final TICI score: \_\_\_\_\_

Time from groin puncture to reperfusion (Clot extraction time): \_\_\_\_\_

Emboli in previous unaffected territory:  Yes  No

Previous stroke(s):  Yes  No

**Prior anticoagulant therapy:**  Yes  No **Prior antiplatelet therapy:**  Yes  No

**Post-operative intracranial hemorrhage:**  None  Symptomatic  Asymptomatic

**Complete blood count:**

Red blood cell count	..... x 10 <sup>6</sup> cells/ $\mu$ l
Platelet count	..... x 10 <sup>3</sup> cells/ $\mu$ l
White blood cell count	..... x 10 <sup>3</sup> cells/ $\mu$ l
Optional	Differential white blood cell counts, hemoglobin, hematocrit, etc.

**Risk factors:**

*Atrial fibrillation:*  Yes  No

*Coronary artery disease:*  Yes  No

*Hypertension:*  Yes  No

*Hypercholesterolemia:*  Yes  No

*Dyslipidemia:*  Yes  No

*Diabetes Mellitus:*  Yes  No

*Smoking:*  Yes  No

**Other comorbidities (e.g. cancer-related events):**

---

---

**Notes:**

